Clinical Effects and Antivenom Dosing in Brown Snake (Pseudonaja spp.) Envenoming — Australian Snakebite Project (ASP-14)

Background Snakebite is a global health issue and treatment with antivenom continues to be problematic. Brown snakes (genus Pseudonaja) are the most medically important group of Australian snakes and there is controversy over the dose of brown snake antivenom. We aimed to investigate the clinical and laboratory features of definite brown snake (Pseudonaja spp.) envenoming, and determine the dose of antivenom required. Methods and Finding This was a prospective observational study of definite brown snake envenoming from the Australian Snakebite Project (ASP) based on snake identification or specific enzyme immunoassay for Pseudonaja venom. From January 2004 to January 2012 there were 149 definite brown snake bites [median age 42y (2–81y); 100 males]. Systemic envenoming occurred in 136 (88%) cases. All envenomed patients developed venom induced consumption coagulopathy (VICC), with complete VICC in 109 (80%) and partial VICC in 27 (20%). Systemic symptoms occurred in 61 (45%) and mild neurotoxicity in 2 (1%). Myotoxicity did not occur. Severe envenoming occurred in 51 patients (38%) and was characterised by collapse or hypotension (37), thrombotic microangiopathy (15), major haemorrhage (5), cardiac arrest (7) and death (6). The median peak venom concentration in 118 envenomed patients was 1.6 ng/mL (Range: 0.15–210 ng/mL). The median initial antivenom dose was 2 vials (Range: 1–40) in 128 patients receiving antivenom. There was no difference in INR recovery or clinical outcome between patients receiving one or more than one vial of antivenom. Free venom was not detected in 112/115 patients post-antivenom with only low concentrations (0.4 to 0.9 ng/ml) in three patients. Conclusions Envenoming by brown snakes causes VICC and over a third of patients had serious complications including major haemorrhage, collapse and microangiopathy. The results of this study support accumulating evidence that giving more than one vial of antivenom is unnecessary in brown snake envenoming.

[1]  D. Hepner,et al.  Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. , 2006, The Journal of allergy and clinical immunology.

[2]  A. Kasturiratne,et al.  The Global Burden of Snakebite: A Literature Analysis and Modelling Based on Regional Estimates of Envenoming and Deaths , 2008, PLoS medicine.

[3]  H. Parkington,et al.  In vivo and in vitro cardiovascular effects of Papuan taipan (Oxyuranus scutellatus) venom: Exploring "sudden collapse". , 2012, Toxicology letters.

[4]  J. Tibballs,et al.  The Efficacy of Antivenom in Prevention of Cardiovascular Depression and Coagulopathy Induced by Brown Snake (Pseudonaja) Species Venom , 1991, Anaesthesia and intensive care.

[5]  S. Donnellan,et al.  A phylogenetic analysis of Pseudonaja (Hydrophiinae, Elapidae, Serpentes) based on mitochondrial DNA sequences. , 2005, Molecular phylogenetics and evolution.

[6]  B. Currie,et al.  Efficacy of antivenom against the procoagulant effect of Australian brown snake (Pseudonaja sp.) venom: in vivo and in vitro studies. , 2007, Toxicon : official journal of the International Society on Toxinology.

[7]  B. Currie,et al.  Snakebite in tropical Australia: a prospective study in the “Top End” of the Northern Territory , 2004, The Medical journal of Australia.

[8]  B. Currie,et al.  Current use of Australian snake antivenoms and frequency of immediate‐type hypersensitivity reactions and anaphylaxis , 2008, The Medical journal of Australia.

[9]  W. Hodgson,et al.  Development of a sensitive enzyme immunoassay for measuring taipan venom in serum. , 2010, Toxicon : official journal of the International Society on Toxinology.

[10]  G. Jelinek,et al.  Admissions for suspected snake bite to the Perth adult teaching hospitals, 1979 to 1988 , 1991, The Medical journal of Australia.

[11]  G. Isbister,et al.  Snakebite Doesn't Cause Disseminated Intravascular Coagulation: Coagulopathy and Thrombotic Microangiopathy in Snake Envenoming , 2010, Seminars in thrombosis and hemostasis.

[12]  G. Isbister,et al.  Commercial monovalent antivenoms in Australia are polyvalent. , 2009, Toxicon : official journal of the International Society on Toxinology.

[13]  N. Dunstan,et al.  Venom yields from Australian and some other species of snakes , 2006, Ecotoxicology.

[14]  D. Warrell.  Snake bite , 2010, The Lancet.

[15]  S. Kuruppu,et al.  Neurotoxins From Australo-Papuan Elapids: A Biochemical and Pharmacological Perspective , 2008, Critical reviews in toxicology.

[16]  G. Jelinek,et al.  Ten years of snake bites at Fremantle Hospital , 1990, The Medical journal of Australia.

[17]  L. Baldwin,et al.  Fatal Brown Snake (Pseudonaja textilis) Envenomation Despite the use of Antivenom , 1993, The Medical journal of Australia.

[18]  S. Sutherland,et al.  Snakebite deaths in Australia 1992‐1994 and a management update , 1995, The Medical journal of Australia.

[19]  B. Currie.  Snakebite in tropical Australia, Papua New Guinea and Irian Jaya , 2000 .

[20]  G. Isbister,et al.  Envenoming by the rough‐scaled snake (Tropidechis carinatus): a series of confirmed cases , 2009, The Medical journal of Australia.

[21]  G. Isbister.  Antivenom efficacy or effectiveness: the Australian experience. , 2010, Toxicology.

[22]  W. Hodgson,et al.  Solving the 'Brown snake paradox': in vitro characterisation of Australasian snake presynaptic neurotoxin activity. , 2012, Toxicology letters.

[23]  G. Isbister,et al.  Endogenous thrombin potential as a novel method for the characterization of procoagulant snake venoms and the efficacy of antivenom. , 2010, Toxicon : official journal of the International Society on Toxinology.

[24]  M. Lavin,et al.  Molecular Diversity in Venom from the Australian Brown Snake, Pseudonaja textilis*S , 2006, Molecular & Cellular Proteomics.

[25]  B. Currie,et al.  Clinical effects and treatment of envenoming by Hoplocephalus spp. snakes in Australia: Australian Snakebite Project (ASP-12). , 2011, Toxicon : official journal of the International Society on Toxinology.

[26]  G. Jelinek,et al.  Antivenom dosing in 35 patients with severe brown snake (Pseudonaja) envenoming in Western Australia over 10 years , 2004, The Medical journal of Australia.

[27]  R. Kini,et al.  Pseutarin C, a Prothrombin Activator from Pseudonaja textilis Venom: Its Structural and Functional Similarity to Mammalian Coagulation Factor Xa-Va Complex , 2002, Thrombosis and Haemostasis.

[28]  G. Jelinek,et al.  Efficacy and Potency of Antivenoms in Neutralizing the Procoagulant Effects of Australian Snake Venoms in Dog and Human Plasma , 1996, Anaesthesia and intensive care.

[29]  S. Brown.  Clinical features and severity grading of anaphylaxis. , 2004, The Journal of allergy and clinical immunology.